Indivumed appoints Dr. Helge Bastian as Managing Director and Chief Commercial Officer

Hamburg (ots) - Indivumed is pleased to announce that Helge
Bastian, Ph.D, will join Indivumed as Managing Director and Chief
Commercial Officer on September 12, 2011.

Hartmut Juhl, founder and CEO of Indivumed, says: "The board and
me personally are proud to have Dr. Bastian with Indivumed today. His
tremendous background, global expertise and leadership experience
will support the further development of our company."

Dr. Bastian has over 19 years of international leadership
experience in corporations serving the molecular biology, life
science research, diagnostics, biotechnology, drug development and
pharmaceutical manufacturing industry. Previously, Dr. Bastian was
Vice President of Global Marketing, Business Development & Strategy
for the Research Biotech business unit and member of the leadership
team at Sigma-Aldrich in St. Louis, USA.

He worked as Executive Vice President of Life Science Services
business unit and member of Senior Executive Management Team at SGS
in Geneva, Switzerland. Dr. Bastian joined SGS after more than eleven
years with QIAGEN in Duesseldorf, Germany, where he held various
management positions, most recently as Vice President Molecular
Diagnostics, Vice President Global Strategic Marketing, Vice
President PreAnalytix and member of executive steering committee.

Dr. Bastian holds a diploma in biology (focus area of
biochemistry) and a Ph.D. in molecular biology. He is an alumnus from
the Max- Planck-Network and the Columbia Business School. "Quickly
translating new molecular discoveries into medical practice to
improve the diagnosis and treatment of diseases that are life-
threatening, such as cancer, is an absolute necessity and addresses a
genuine demand," Dr. Bastian explains his decision to join Indivumed.
"As a strong believer in personalized medicine approaches, I am
extremely intrigued by Indivumed's approach to improve cancer
research and drug development, and I am excited about having the
opportunity to further expand the Indivumed product and service
portfolio."

About Indivumed

Indivumed GmbH was founded in 2002 and maintains the world's
leading tumor database and high-quality biobank for the development
of new cancer diagnostics and therapies. The biotechnology company
provides a unique research infrastructure through collaboration with
clinics, oncology networks and special technologies and is recognized
by numerous pharmaceutical companies and leading academic
institutions as a quality-focused research partner and service
provider. With an extraordinary collection of biological samples
taken from more than 13,000 cancer patients, Indivumed provides
research services such as immunohistochemical screening, profiling of
new anti-cancer agents on viable primary tumor tissues, a wide range
of biospecimen formats taken from Indivumed's own biobank and other
research services with a focus on analyzing pathways relevant to
cancer and new targeted therapeutics.

In 2008, Indivumed, together with scientists from the John Hopkins
University in Baltimore, founded Inostics GmbH, a biotech company
that specializes in DNA diagnostics. Indivumed has its main office in
Hamburg and a subsidiary, Indivumed Inc., in Kensington, Maryland,
USA. For more information, please visit www.indivumed.com .

Press contact:
Camilla Piper
Vice President Marketing & Sales

T: +49-40-413383-18
M: +49-151-18233618
F: +49-40-413383-14
E: piper@indivumed.com
www.indivumed.com